Larimar Therapeutics Inc recorded a cumulative net loss of $-173 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 363 other companies achieving higher income per employee. While Larimar Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 3982 to 3992.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

LRMR Net Income per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Net Income Change	-	-	-	-	-
Net Income per Employee (TTM) $	-2,431,056	-2,338,099	-2,333,423	-1,859,141	-1,405,437
LRMR's Total Ranking	# 3992	# 3982	# 3095	# 3631	# 3339
Seq. Net Income Change	-	-	-	-	-

LRMR Company Profile >> Back to LRMR Efficiency Comparisons >> Compare LRMR Net Income per Employee to its Competitors

LRMR Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 364
Healthcare Sector	# 801
Overall Market	# 3992

Net Income per Employee Statistics
High	Average	Low
$ -457,085	$ -858,721	$ -2,338,099
(Sep 30 2020)		(Mar 31 2026)

News about Larimar Therapeutics Inc Income per employee

Larimar Therapeutics Raises $172.5 Million in Successful Public Offering, Driving Innovation in Rare Disease Treatment Sector

BALA CYNWYD, Pa., Feb. 16, 2024 - Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a leading biotechnology company specializing in the development of treatments for rare diseases, has successfully completed its underwritten public offering of common stock. The offering, which included the full exercise of the underwriter s option to purchase additional shares, raised approximately $172.5 million for the company.
This significant milestone marks a major achievement for Larimar as it continues to advance its innovative therapies for complex rare diseases. The successful completion of this offering demonstrates strong investor confidence in Larimar s groundbreaking research and development efforts.

Larimar Therapeutics Aims to Secure Future with Proposed Underwritten Public Offering

Larimar Therapeutics Proposed Underwritten Public Offering and its Implications
Larimar Therapeutics, a clinical-stage biotechnology company specializing in developing treatments for complex rare diseases, recently made an important announcement regarding its future plans. The company has commenced an underwritten public offering, involving the sale of shares of its common stock and pre-funded warrants to purchase shares of common stock. This decision comes as Larimar aims to secure funding for its ongoing research and development efforts.
As part of the proposed offering, Larimar is expected to grant the underwriters a 30-day option to purchase up to an additional 15% of the securities. This would provide the company with additional financial flexibility if market conditions are favorable. However, it is important to note that the completion of the offering, as well as its actual size and terms, is subject to market and other conditions.

Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector

Income per Employee

Income 12 month ending Jun 30 2026

Number of Employees Jun 30 2026

Date modified: 2026-08-31T03:09:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.